Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Peposertib + Avelumab + Radiation for Hepatobiliary Cancer
Recruiting1 awardPhase 1 & 2
Chicago, Illinois
This trial is testing peposertib, in combination with avelumab and hypofractionated radiation therapy, as a potential new treatment for patients with solid tumors and hepatobiliary malignancies.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.